Armata Pharmaceuticals Inc (NYSEAMERICAN: ARMP) is climbing in the market this morning, and for good reason. The company announced the publication of positive clinical data, exciting investors and sending the stock running for the top. Today, we’ll talk about:
- The data presentation;
- what we’re seeing from ARMP stock as a result; and
- what we’ll be watching for ahead.
ARMP Announces Data Publication
As mentioned above, Armata Pharmaceuticals is having a great start to the trading session this morning after announcing the publication of data. The announcement came by way of press release early this morning.
In the release, ARMP announced the publication of a case study that involved a cystic fibrosis patient that was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection. The treatment provided was the company’s natural phage product, known as AP-PA01.
The paper was published in the peer-reviewed journal, Infection, and is titled “Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient.
In a statement, Todd R. Patrick, CEO at ARMP, had the following to offer:
The publication of this successful treatment case study, with an Armata phage administered through our single-patient expanded access program, adds to the impressive and growing body of evidence demonstrating the effectiveness of our phage product candidates, and bacteriophage in general.
To solidify our position as a leader in the development of phage-based therapeutics, we are currently working with key opinion leaders to map out an efficient clinical strategy for both our Pseudomonas and Staphylococcus phage product candidates, and plan to file an IND later this year for our Staphylococcus phage candidate. Treatment of single patients through the expanded access program has been very helpful in demonstrating the promise of phage therapy.
However, the reality is that supporting compassionate use cases limits our ability to focus our resources on formal clinical trials required for FDA approval to bring a potential solution to all patients suffering from drug-resistant bacterial infections. With the growing threat of antimicrobial resistance, it is extremely important that we take the necessary steps to perform rigorous clinical trials so we can move toward commercialization of alternatives to traditional antibiotics.
As such, we plan to end our single-patient expanded access program and instead focus on demonstrating phage efficacy through well-powered clinical trials. The work in these two lead programs will pave the way for development of new phage product candidates, natural or synthetic, that address additional unmet medical need and create new opportunities for corporate or government partnerships.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. When it comes to Armata Pharmaceuticals, the news proved to be overwhelmingly positive.
After all, the published data further validates the work that it is dowing with AP-PA01. So, it’s not surprising to see that excited investors are pushing the stock on a run for the top.
As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:28), ARMP is trading at $4.18 per share after a gain of $1.01 per share or 32.05% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ARMP. In particular, we’re interested in following the story usrrounding its AP-PA01 product and the coming formulation of a new product called AP-PA02. Nonetheless, we’ll keep a close eye on the story and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!